Biologic medications such as anakinra, which targets IL-1, have been used for refractory cases of MIS-C due to its effectiveness in similar hyperinflammatory diseases such as KD and macrophage activation syndrome (MAS) [12, 13]. This evidence concerns the gene IL1B and macrophage activation syndrome.